Patents by Inventor Valentina Screpanti Sundquist

Valentina Screpanti Sundquist has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CHOLERA VACCINE FORMULATION
    Publication number: 20230372464
    Abstract: Described herein are dry compositions that can be stored at ambient temperature without major loss of potency.
    Type: Application
    Filed: October 6, 2021
    Publication date: November 23, 2023
    Applicant: VALNEVA SWEDEN AB
    Inventors: Valentina Screpanti-Sundquist, Janet Hoogstraate, Fredrik Bylund
  • Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other ?-synucleinopathies
    Patent number: 9084832
    Abstract: In an in vivo method for detecting ?-synuclein protofibrils in human tissue, an antibody or fragment thereof is administered to a human. The antibody or fragment is labelled with a detectable label. A complex formed between the antibody or fragment and ?-synuclein protofibrils in the human tissue is detected. The antibody or fragment has high affinity for human ?-synuclein protofibrils and low affinity for ?-synuclein monomers and has a combination of three specified variable heavy (VH) CDR sequences and three specified variable light (VL) CDR sequences.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: July 21, 2015
    Assignee: BioArctic Neuroscience AB
    Inventors: Eva Nordström, Alex Kasrayan, Monica Ekberg, Valentina Screpanti Sundquist, Lars Lannfelt, Mats Holmquist
  • Protofibril-Binding Antibodies And Their Use In Therapeutic And Diagnostic Methods For Parkinson's Disease, Dementia With Lewy Bodies And Other Alpha-Synucleinopathies
    Publication number: 20150139900
    Abstract: An in vivo method for detecting ?-synuclein protofibrils in human tissue comprises administering an antibody or fragment thereof to a human, wherein the antibody or fragment thereof is labelled with a detectable label, and detecting a complex formed between the antibody or fragment thereof and ?-synuclein protofibrils in the human tissue. The antibody or fragment thereof has high affinity for human ?-synuclein protofibrils and low binding of ?-synuclein monomers and has a combination of three specified variable heavy (VH) CDR sequences and three specified variable light (VL) CDR sequences.
    Type: Application
    Filed: February 2, 2015
    Publication date: May 21, 2015
    Inventors: Eva Nordström, Alex Kasrayan, Monica Ekberg, Valentina Screpanti Sundquist, Lars Lannfelt, Mats Holmquist
  • Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for Parkinson's disease, dementia with lewy bodies and other ?-synucleinopathies
    Patent number: 8968734
    Abstract: Antibodies and fragments thereof have high affinity for human ?-synuclein protofibrils and low binding of ?-synuclein monomers, wherein the antibodies or fragments have specified Complementarity Determining Region (CDR) sequences. Compositions comprise such an antibody or fragment and methods of detecting ?-synuclein protofibrils use such an antibody or fragment. In further embodiments, methods of preventing, delaying onset of or treating a neurodegenerative disorder with ?-synuclein pathology comprise administering such an antibody or fragment, and such an antibody or fragment is used in the manufacture of a pharmaceutical composition for treatment of a neurodegenerative disorder with ?-synuclein pathology. Such an antibody or fragment is used in the diagnosis or monitoring of the development of a neurodegenerative disorder with ?-synuclein pathology, and in methods for reducing or inhibiting ?-synuclein aggregation by administration of such an antibody or fragment.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: March 3, 2015
    Assignee: BioArctic Neuroscience AB
    Inventors: Eva Nordström, Alex Kasrayan, Monica Ekberg, Valentina Screpanti Sundquist, Lars Lannfelt, Mats Holmquist
  • Protofibril-Binding Antibodies And Their Use In Therapeutic And Diagnostic Methods For Parkinson's Disease, Dementia With Lewy Bodies And Other Alpha-Synucleinopathies
    Publication number: 20140363447
    Abstract: Antibodies and fragments thereof have high affinity for human ?-synuclein protofibrils and low binding of ?-synuclein monomers, wherein the antibodies or fragments have specified Complementarity Determining Region (CDR) sequences. Compositions comprise such an antibody or fragment and methods of detecting ?-synuclein protofibrils use such an antibody or fragment. In further embodiments, methods of preventing, delaying onset of or treating a neurodegenerative disorder with ?-synuclein pathology comprise administering such an antibody or fragment, and such an antibody or fragment is used in the manufacture of a pharmaceutical composition for treatment of a neurodegenerative disorder with ?-synuclein pathology. Such an antibody or fragment is used in the diagnosis or monitoring of the development of a neurodegenerative disorder with ?-synuclein pathology, and in methods for reducing or inhibiting ?-synuclein aggregation by administration of such an antibody or fragment.
    Type: Application
    Filed: August 28, 2014
    Publication date: December 11, 2014
    Inventors: Eva Nordström, Alex Kasrayan, Monica Ekberg, Valentina Screpanti Sundquist, Lars Lannfelt, Mats Holmquist
  • Protofibril-binding antibodies and their use in thereapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
    Patent number: 8859501
    Abstract: Antibodies and fragments thereof have high affinity for human ?-synuclein protofibrils and low binding of ?-synuclein monomers, wherein the antibodies or fragments have specified Complementarity Determining Region (CDR) sequences. Compositions comprise such an antibody or fragment and methods of detecting ?-synuclein protofibrils use such an antibody or fragment. In further embodiments, methods of preventing, delaying onset of or treating a neurodegenerative disorder with ?-synuclein pathology comprise administering such an antibody or fragment, and such an antibody or fragment is used in the manufacture of a pharmaceutical composition for treatment of a neurodegenerative disorder with ?-synuclein pathology. Such an antibody or fragment is used in the diagnosis or monitoring of the development of a neurodegenerative disorder with ?-synuclein pathology, and in methods for reducing or inhibiting ?-synuclein aggregation by administration of such an antibody or fragment.
    Type: Grant
    Filed: August 1, 2013
    Date of Patent: October 14, 2014
    Assignee: BioArctic Neuroscience AB
    Inventors: Eva Nordström, Alex Kasrayan, Monica Ekberg, Valentina Screpanti Sundquist, Lars Lannfelt, Mats Holmquist
  • Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for Parkinson's disease, dementia with lewy bodies and other ?-synucleinopathies
    Patent number: 8632776
    Abstract: Antibodies and fragments thereof have high affinity for human ?-synuclein protofibrils and low binding of ?-synuclein monomers, wherein the antibodies or fragments have specified Complementarity Determining Region (CDR) sequences. Compositions comprise such an antibody or fragment and methods of detecting ?-synuclein protofibrils use such an antibody or fragment. In further embodiments, methods of preventing, delaying onset of or treating a neurodegenerative disorder with ?-synuclein pathology comprise administering such an antibody or fragment, and such an antibody or fragment is used in the manufacture of a pharmaceutical composition for treatment of a neurodegenerative disorder with ?-synuclein pathology. Such an antibody or fragment is used in the diagnosis or monitoring of the development of a neurodegenerative disorder with ?-synuclein pathology, and in methods for reducing or inhibiting ?-synuclein aggregation by administration of such an antibody or fragment.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: January 21, 2014
    Assignee: BioArctic Neuroscience AB
    Inventors: Eva Nordström, Alex Kasrayan, Monica Ekberg, Valentina Screpanti Sundquist, Lars Lannfelt, Mats Holmquist
  • Protofibril-Binding Antibodies And Their Use In Therapeutic And Diagnostic Methods For Parkinson's Disease, Dementia With Lewy Bodies And Other Alpha-Synucleinopathies
    Publication number: 20130309251
    Abstract: Antibodies and fragments thereof have high affinity for human ?-synuclein protofibrils and low binding of ?-synuclein monomers, wherein the antibodies or fragments have specified Complementarity Determining Region (CDR) sequences. Compositions comprise such an antibody or fragment and methods of detecting ?-synuclein protofibrils use such an antibody or fragment. In further embodiments, methods of preventing, delaying onset of or treating a neurodegenerative disorder with ?-synuclein pathology comprise administering such an antibody or fragment, and such an antibody or fragment is used in the manufacture of a pharmaceutical composition for treatment of a neurodegenerative disorder with ?-synuclein pathology. Such an antibody or fragment is used in the diagnosis or monitoring of the development of a neurodegenerative disorder with ?-synuclein pathology, and in methods for reducing or inhibiting ?-synuclein aggregation by administration of such an antibody or fragment.
    Type: Application
    Filed: August 1, 2013
    Publication date: November 21, 2013
    Applicant: BIOARCTIC NEUROSCIENCE AB
    Inventors: Eva Nordström, Alex Kasrayan, Monica Ekberg, Valentina Screpanti Sundquist, Lars Lannfelt, Mats Holmquist
  • Protofibril-Binding Antibodies and Their Use in Therapeutic and Diagnostic Methods for Parkinson's Disease, Dementia with Lewy Bodies and Other Alpha-Synucleinopathies
    Publication number: 20120308572
    Abstract: Antibodies and fragments thereof have high affinity for human ?-synuclein protofibrils and low binding of ?-synuclein monomers, wherein the antibodies or fragments have specified Complementarity Determining Region (CDR) sequences. Compositions comprise such an antibody or fragment and methods of detecting ?-synuclein protofibrils use such an antibody or fragment. In further embodiments, methods of preventing, delaying onset of or treating a neurodegenerative disorder with ?-synuclein pathology comprise administering such an antibody or fragment, and such an antibody or fragment is used in the manufacture of a pharmaceutical composition for treatment of a neurodegenerative disorder with ?-synuclein pathology. Such an antibody or fragment is used in the diagnosis or monitoring of the development of a neurodegenerative disorder with ?-synuclein pathology, and in methods for reducing or inhibiting ?-synuclein aggregation by administration of such an antibody or fragment.
    Type: Application
    Filed: February 25, 2011
    Publication date: December 6, 2012
    Applicant: BioArctic Neuroscience AB
    Inventors: Eva Nordström, Alex Kasrayan, Monica Ekberg, Valentina Screpanti Sundquist, Lars Lannfelt, Mats Holmquist